The epidemiology of coeliac disease (CD) is changing. Presentation of CD with malabsorptive symptoms or malnutrition is now the exception rather than the rule and, it now affects those underweight and overweight equally. In concert with these epidemiological shifts, the incidence of CD is increasing. These changing patterns of disease presentation are challenging traditional management paradigms, and clinicians now need to adapt to these changes and respond to the demands of an increasingly well-informed consumer population. This article aims to provide historical context to the epidemiological changes in CD, which provides context to direct future research. Changing definitions and diagnostic paradigms are complicating the management of CD. The gold standard of diagnosis, treatment goals, guidelines for follow-up, and the role of population screening in CD remain controversial and unresolved. Although the patient population is interested in new treatments for CD and alternatives to a gluten-free diet, most therapies are not yet widely available or sufficiently researched, and our understanding of the natural history of CD is limited despite a number of retrospective and populationbased studies. The management of asymptomatic CD has only recently been examined despite up to half of patients now presenting with no or minimal symptoms. There is surprisingly little evidence to resolve many of these issues, and only with robust prospective studies will our understanding of the true natural history of coeliac disease be clarified.
Introduction
For at least the past two centuries, the clinical syndrome of coeliac disease (CD) has been recognized and described. Although relatively little progress was made in CD from the initial descriptions by Aretaeus of Cappadocia, the 20th century heralded significant advances in our understanding and management of CD. Samuel Gee described CD as "a kind of chronic indigestion" of his works in 1918 and was the first to draw the connection to treatment with diet, although the precise dietary trigger remained obscure. 1 In the 1950s, Willem Dicke transformed the treatment of CD by identifying the causative agent when wheat was removed and then reintroduced to the food supply in Holland during and after the second World War. 2 Subsequent advances in the 1960s resulted in the demonstration of the defining intestinal pathology and then the reversal of this histology upon institution of a gluten free diet (GFD) .
At the heart of many of these early observations was a syndrome of profound malnutrition. Published images from the time of Samuel Gee and Willem-Karel Dicke show children with muscle wasting and abdominal distension while the clinical descriptions were of steatorrhoea and "food having undergone putrefecation rather than concoction." 3 Later case series describe an incidence of malignancy of up to 20%. 4 What is clear, now in the 21st century, is that this epidemiology has changed dramatically. No longer is CD a condition purely of malnutrition, malabsorption, and failure to thrive. CD is affecting those overweight as much as underweight, it is increasingly being identified in asymptomatic individuals, and the incidence is rising, independent of physician recognition and community awareness. Despite this epidemiological shift, our approach to management has changed little. The prescription of a gluten-free diet to a patient with malnutrition and symptoms is a relatively easy decision for both the clinician and the patient. But what of the increasing population we are diagnosing with asymptomatic CD?
Two centuries-one treatment
The advances outlined previously revolutionized the management of what had previously been a disabling condition with a high rate of complications. Treatment with a GFD has subsequently been applied to CD in adults, those detected through targeted screening and asymptomatic individuals. However, there is surprisingly little evidence to guide such an approach. To date, there have been no randomized, double blind, placebo controlled trials in the management of CD with a GFD nor there are likely to be such trials for a condition where the gold standard of treatment has been so widely adopted. As a result of this treatment paradigm, most evidence for the benefit of treatment has been derived from retrospective or population-based studies. While these studies have provided important insights, they often do not allow for dissection of issues such as dietary compliance or antibody response while the lack of defined time points for follow-up result in statistical assumptions needing to be made about the timing of disease response. Further complicating these studies is a lack of consensus as to the definition of treatment response. Intuitively, resolution of symptoms, normalization of histology, and normalization of coeliac antibodies should define response to treatment. But asymptomatic CD may occur in up to 50% of affected individuals, 5 symptoms correlate poorly with mucosal pathology, 6 and even with excellent dietary adherence, histology and coeliac antibodies can take several years to normalize. 7 The situation is complex, and there is a paucity of prospective studies examining these and other outcomes such as body composition and bone mineral density.
The GFD itself is also not without its problems. The GFD can be socially isolating, expensive, compliance is variable, and the nutritional adequacy has also been questioned. [8] [9] [10] Even the definition of "gluten free" has generated controversy. Only recently have the Food and Drug Administration in the United States agreed to establishing a threshold of 20 parts per million (ppm) as gluten free to align with Europe, but consensus definitions have yet to be established in Australia and New Zealand where the threshold remains at the lowest detectable amount (currently 3 ppm).
Asymptomatic coeliac disease and the challenge of under-diagnosis
As many as seven in eight people with CD are undiagnosed. Under-diagnosis can be contributed to by such factors and community awareness, socioeconomic factors, and availability of endoscopy services. To overcome this issue, population screening continues to attract attention and has gained traction in countries such as Finland. However, screening standards demand that the long-term disease outcomes be known and that treatment will prevent complications. 12 As with all population screening programs, the implications are particularly relevant to those who are asymptomatic. An increasing proportion of patients with CD are presenting with minimal or no gastrointestinal symptoms, and this patient group can be most challenging to manage, particularly with regards to encouragement of dietary compliance. In clinical practice, patients in this group question what benefits there are to them as an individual. In a recent study of 40 asymptomatic adults with untreated CD randomized to a GFD or gluten-containing diet, gastrointestinal symptoms, histology, and coeliac antibodies improved in those randomized to a GFD, but there were no differences in bone mineral density or body composition indices. 13 Although symptoms might improve with treatment, health authorities will only embrace screening when cost effectiveness is supported by more robust public health outcomes such as mortality, fracture risk, or the incidence of malignancy. As it stands, controversy continues around these issues in CD. For example, although intuitive that treatment might reduce the incidence of malignancies seen in CD, there is only scant evidence to support such a contention, 14, 15 and there are no prospective studies to guide us. One approach might be to target at-risk populations. Genotype testing helps this approach, but up to 56% of the population carry the susceptibility genotype. 16 Affected individuals might also be identified by targeting those with gastrointestinal symptoms or altered body composition, but results from large-scale screening studies using this strategy have been disappointing.
17,18
The way forward-robust prospective studies A recent study by this author and others followed a cohort of patients with newly diagnosed CD prospectively for 5 years. 7 In this group of patients, it was shown that although mucosal response occurs in the vast majority (89%) at 5 years, half had mild ongoing mucosal inflammation (Marsh 1 or worse) . In addition, only 37% had achieved mucosal remission at 1 year. This was despite excellent dietary adherence in the overwhelming majority of patients. Importantly, it was shown that coeliac antibodies were not an accurate marker of mucosal inflammation during follow-up. Important insights were also gained into the changes in body composition. Weight and fat mass increased, and bone density improved, particularly in those with reduced density at baseline. When viewed together, these prospectively collected results serve to provide tangible outcomes for patients and clinicians.
For clinicians, prospective studies provide insights into the expected timelines of response to treatment of both antibodies and histology. Importantly, the results prospective studies undertaken thus far imply care should be taken in interpreting coeliac antibodies as reflecting mucosal disease activity. Caution should also be exercised in attributing elevated antibodies to dietary indiscretion, particularly in view of the finding of mucosal response in most of this and other cohorts. 19 Population studies have shown ongoing mucosal inflammation increases risks of complications such as lymphoma, and this supports the intuition that mucosal healing should be a treatment goal in CD.
14 Although histological follow-up may be the most accurate means of assessment in CD, it is impractical for an increasingly stretched healthcare system. Prospective studies will inform clinicians regarding histological response, and large studies of this nature should enable identification of robust risk factors for mucosal response. It remains intuitive that mucosal remission be the desired endpoint in a condition defined by the mucosal pathology and there are documented consequences of even mild ongoing inflammation. 20 Other inflammatory bowel diseases have similarly adverse consequences in the absence of mucosal disease response. 21 Underpinning treatment of most inflammatory disease has been induction (often with corticosteroids) followed by maintenance therapy (usually an immunomodulator such as azathioprine, methotrexate, or monoclonal antibodies). Although CD is by definition an inflammatory bowel disease, clinicians have thus far not embraced treating it as such. Our approach has been to commence maintenance therapy (i.e. a gluten-free diet). As demonstrated by the studies outlined previously, such maintenance therapy can take a prolonged period to achieve histological and serological response. Results of studies examining induction therapy are awaited. 22 Interest in therapeutics for CD has increased, and from the patient perspective, alternatives to the gluten-free diet are highly desirable. 23 The detailed understanding of CD has enabled specific therapies to be developed. 24 Because of cost and resourcing, it is unlikely that therapy will be indicated or funded for all with CD. As seen with other inflammatory bowel diseases, clinicians, will be asked to identify patients who will benefit the most from treatment. Prospective studies with well-defined patient groups including genotypic, serological, and histological markers will further inform these treatment algorithms. Non-invasive markers such as i-FABP, antibodies to glycoprotein-2, and urinary volatile organic compound analysis require validation in prospective studies to overcome the need for regular endoscopic assessment in future studies.
As demonstrated in studies of high-risk populations, 25 genotype dose of HLA-DQ2 has an impact upon disease presentation and possibly on long-term outcomes such as mucosal and serological disease response. These observations are beginning to be adopted into diagnostic algorithms and might serve to identify high-risk groups that warrant more stringent disease follow-up or groups that should receive therapy earlier in their disease course. 16 Genome wide association studies have thus far been exclusively applied to understanding at-risk groups, disease association or for investigating the pathogenesis of CD. 26 Whether any of these risk loci are associated with long-term disease outcomes (and therefore able to be utilized in risk-assessment algorithms) has not been assessed and should be included in future prospective analyses.
A significant weakness of all clinical studies in CD to date has been the absence of an objective measure of dietary compliance. Coeliac antibodies, intestinal histology, and symptoms are all imperfect tools for assessment of adherence. More robust and validated tools for assessment of compliance have been subsequently developed, but they remain subjective. 27 There is a pressing need for objective measures. The measurement of intact gluten peptides in the feces has presented one realistic alternative that requires validation 28 while newer technologies such as measurement of the metabolome (in serum or urine) 29 or measurement of volatile compounds in the urine 30 also have potential. Techniques that allow real-time assessment of gluten peptides in food may have a role in avoiding inadvertent gluten exposure but require further development. 31 
Conclusion and future directions
The high incidence of CD compared with other inflammatory bowel disease and availability of validated outcome scores should facilitate the conduct of large-scale prospective studies. Clinicians require clarity in identifying those patients likely to have a more severe disease course in order that such patients are targeted for more intensive surveillance and potential therapies. Further, the utility of novel non-invasive markers can only be accurately assessed in sufficiently powered studies. Participants in these studies need to be clearly defined and characterized at diagnosis and have histological follow-up at predetermined time intervals. Contemporaneous measurement of coeliac antibodies, routine blood tests, genotype (both HLA and non-HLA genes), and noninvasive markers of intestinal healing is paramount if our understanding of the true natural history of CD is to be progressed.
